Back to News
Market Impact: 0.35
Syndax Pharmaceuticals Suffers Pipeline Blow
Source: benzinga.com
Healthcare & BiotechCompany Fundamentals
Syndax Pharmaceuticals will halt development of axatilimab for idiopathic pulmonary fibrosis after the drug missed the primary endpoint in the Phase 2 MAXPIRe trial. The setback applies to this indication; the article provides no further trial results or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.40
Ticker Sentiment
SNDX-0.85
More News
- Why UnitedHealth Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
- Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- Stocks making the biggest moves premarket: JPMorgan Chase, Micron, UnitedHealth & more
- Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
- Stocks making the biggest moves midday: Apple, Meta Platforms, Bumble, Fermi, Goldman Sachs & more
- South Korean carmaker Hyundai plans 'strategic' investment of $15.5 billion in India by 2032
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Analyze SEC Filings With AI: A Verification-First Guide
- AI for IR Street Intelligence: Notes, Estimates, and Peers